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Physiological function of 
phospholipase D2 in anti-tumor 
immunity: regulation of CD8+ T 
lymphocyte proliferation
Van Ngo Thai Bich1, Tsunaki Hongu1, Yuki Miura1, Naohiro Katagiri1, Norihiko Ohbayashi1, 
Yumi Yamashita-Kanemaru2, Akira Shibuya2,3, Yuji Funakoshi1 & Yasunori Kanaho1
Two major phospholipase D (PLD) isozymes in mammals, PLD1 and PLD2, hydrolyze the membrane 
phospholipid phosphatidylcholine to choline and the lipid messenger phosphatidic acid. Although 
their roles in cancer cells have been well studied, their functions in tumor microenvironment have 
not yet been clarified. Here, we demonstrate that PLD2 in cytotoxic CD8+ T cells plays a crucial role 
in anti-tumor immunity by regulating their cell proliferation. We found that growth of tumors formed 
by subcutaneously transplanted cancer cells is enhanced in Pld2-knockout mice. Interestingly, this 
phenotype was found to be at least in part attributable to the ablation of Pld2 from bone marrow 
cells. The number of CD8+ T cells, which induce cancer cell death, significantly decreased in the tumor 
produced in Pld2-knockout mice. In addition, CD3/CD28-stimulated proliferation of primary cultured 
splenic CD8+ T cells is markedly suppressed by Pld2 ablation. Finally, CD3/CD28-dependent activation of 
Erk1/2 and Ras is inhibited in Pld2-deleted CD8+ T cells. Collectively, these results indicate that PLD2 in 
CD8+ T cells plays a key role in their proliferation through activation of the Ras/Erk signaling pathway, 
thereby regulating anti-tumor immunity.
The tumor microenvironment is comprised of cancer cells and numerous components such as blood vessels, 
fibroblasts, bone marrow-derived inflammatory cells, the extracellular matrix, and immune cells1. Under patho-
physiological conditions, immune cells have reciprocal potentials being able to interfere with tumor develop-
ment and promote the tumor growth. During tumor progression, effector cells of innate and adaptive immune 
responses recognize and attack tumor cells2,3, resulting in elimination of tumor cells from the human body. On 
the other hand, some other types of immune cells promote tumor growth by inhibiting anti-tumor immune 
responses, inducing inflammation and producing pro-tumoral cytokines and chemokines3. Lymphocytes infil-
trate into tumor microenvironment of cancer patients and the presence of higher number of cytotoxic CD8+ T 
cells in solid tumors is associated with improved survival of patients with breast cancer, renal cell carcinoma, 
melanoma, and ovarian cancer4,5. Therefore, elucidation of the mechanisms for regulation of the development of 
T lymphocytes and their anti-tumor activity could provide insight into cancer immunotherapeutic opportunities.
Development of naïve T cells to effector T cells, which are capable of infiltrating into infected tissues or 
tumors to eliminate target cells, is initiated by engagement of the T cell receptor (TCR) of the naïve T cell and 
antigen-presenting cells: upon TCR activation in the lymphoid organs, naïve T cells, which are differentiated 
from precursor T cells in the thymus, undergo clonal expansion, proliferation and differentiation to become 
effector and memory T cells6,7. Engagement of TCR activates a number of downstream signaling pathways, such 
as MAPK8, NF-κB6,9, calcium10 and lipid signaling pathways, which control the developmental process from naïve 
T cells to effector T cells.
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Two mammalian isozymes of phospholipase D (PLD), PLD1 and 2, which catalyze hydrolysis of membrane 
phosphatidylcholine (PC) to choline and the signaling lipid phosphatidic acid (PA), are involved in various cellu-
lar functions such as vesicular trafficking, the intracellular secretory response, cell motility and cell proliferation, 
through the product PA11. Several lines of evidence suggested that these PLDs are involved in immune responses 
and cancer progression. Primary macrophages lacking either PLD1 or PLD2 exhibit impaired phagocytosis and 
cell migration due to abnormal cytoskeletal organization12. PLDs are also suggested to function in Jurkat T cell 
activation13. Recently, we have reported that PLD1 in vascular endothelial cells is involved in tumor growth 
through the promotion of tumor angiogenesis in mice14. It has also been shown that expression of the inactive 
PLD2 mutant in EL4 lymphoma cells reduces their proliferation rate and invasiveness15. In addition, overexpres-
sion of PLD2 in low-invasive breast cancer cell line MCF-7 cells promotes tumor growth in severe combined 
immunodeficiency (SCID) mice, while silencing of PLD2 in highly-invasive breast cancer cell line MDA-MB-231 
cells significantly abrogates lung metastases in SCID mice16, suggesting that PLD2 in these cancer cells plays a 
pivotal role in cancer progression. However, neither the involvement of PLD2 in the tumor microenvironment 
nor the link between PLD2-mediated immune responses and tumor immunity has been elucidated.
In the present study, we provide evidence that PLD2 positively regulates proliferation of CD8+ T cells, which 
have a critical function in cancer cell elimination, through TCR-dependent activation of the Ras-Erk signaling 
pathway, thereby contributing to the suppression of tumor progression.
Result
Ablation of Pld2 promotes the tumor growth. To explore the pathological roles of PLD2, we analyzed 
growth of tumors produced by implantation of B16 melanoma and Lewis lung carcinoma (LLC) cells into Pld2-
knockout (Pld2−/−) mice, which had been generated in our laboratory17. Unlike the previous reports showing 
tumor-progressive functions of PLDs14,16, tumor growth was significantly enhanced in Pld2−/− mice (Fig. 1a–d).
Since Pld2−/− mice had been generated by replacing exons 14 and 15 of the Pld2 gene17 (Supplementary 
Fig. S1), we cannot rule out the possibility that a partial peptide(s) of PLD2 is expressed in the mice and exerts 
an off-target effect. To exclude this possibility, we generated new Pld2-null mice (Pld2−/−/Cas9) with the 
CRISPR-Cas9 technique to delete most of the coding regions of PLD2 (Supplementary Fig. S2). Consistent 
with the result obtained with Pld2−/− mice (Fig. 1), Pld2−/−/Cas9 mice implanted with B16 melanoma and LLC 
cells enhanced tumor growth (Supplementary Fig. S3), confirming that ablation of Pld2 promotes the tumor 
growth.
Figure 1. Tumor growth is enhanced in Pld2−/− mice. B16 melanoma (B16) (a,b) and Lewis lung carcinoma 
(LLC) cells (c,d) were implanted into WT (n = 8) and Pld2−/− mice (n = 6), and tumor volumes were measured 
every other day after sixth day of implantation (a,c). Tumors produced by B16 and LLC cells were dissected 
at 16 (b) and 18 days (d), respectively, and their weight was measured and shown as means ± SEM. *p < 0.05, 
**p < 0.01.
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Ablation of Pld2 inhibits tumor cell apoptosis without effect on tumor angiogenesis. Tumor 
angiogenesis is the critical event for tumor growth18. Although the previous studies have shown that PLD1 is 
involved in tumor angiogenesis14, ablation of Pld2 did not affect tumor angiogenesis (Fig. 2a): immunofluores-
cence staining for the endothelial cell marker CD31 and the matured blood vessel marker α-smooth muscle actin 
(α-SMA) revealed that the number and area of blood vessels and number of matured vessels in B16 melanoma 
tumors formed in Pld2−/− mice were comparable with those in wild-type (WT) mice. Thus, enhancement of 
tumor growth in Pld2−/− mice is not related to tumor angiogenesis.
Imbalance between apoptosis and proliferation of tumor cells is a hallmark underlying tumor progression. 
TUNEL assay revealed less apoptotic cells in B16 melanoma tumors formed in Pld2−/− mice (Fig. 2b). When 
B16 melanoma cells stably expressing the fluorescent protein mCherry were implanted, apoptosis of these cells 
in the tumor formed in Pld2−/− mice was significantly suppressed (Fig. 2c), which was consistent with the result 
of immunostaining of cleaved caspase 3, a specific marker for apoptotic cells (Fig. 2d). These results indicate that 
death of tumor cells is inhibited in Pld2−/− mice.
PLD2 in CD8+ T cells is required for tumor growth suppression. For cancer cells to proliferate and 
form solid tumors, they have to overcome an anti-tumor immune response coordinated by innate and adaptive 
immune cells19. This concept and results shown above led us to assume that Pld2−/− mice are defective for the 
anti-tumor immune system. To evaluate this assumption, we conducted bone marrow transplantation experi-
ments. Bone marrow reconstitution efficiency was more than 95% as assessed by percentage of CD45.1-expressing 
donor haematopoietic stem cells in CD45.2+ recipient mice (Fig. 3a). Consistent with the result with Pld2−/− mice 
(Fig. 1a,b), growth of the tumor produced by B16 melanoma cells in Pld2−/− mice grafted with Pld2−/− bone 
marrow cells (rKOdKO) was significantly enhanced compared with that in WT mice grafted with control bone 
marrow cells (rWTdWT) (Fig. 3b). Tumor growth in WT mice transplanted with Pld2−/− bone marrow cells 
(rWTdKO) was promoted compared with that in rWTdWT. In addition, reconstitution of WT bone marrow 
cells into Pld2−/− mice (rKOdWT) significantly suppressed the tumor-progressive phenotype of rKOdKO mice. 
These results demonstrate that PLD2 in bone marrow cells is crucial for tumor growth suppression. However, 
extent of tumor growth in rWTdKO was less than that in rKOdKO (Fig. 3b), indicating that PLD2 in other cell 
types distinct from bone marrow cells is also involved in the tumor growth suppression. This is supported by 
the results that Pld2−/− mice reconstituted with WT bone marrow cells (rKOdWT) tended to slightly augment 
tumor growth compared with rWTdWT (Fig. 3b). Nevertheless, these results provide evidence that PLD2 in bone 
marrow-derived cells at least in part functions in anti-tumor immune responses.
Helper CD4+ and cytotoxic CD8+ T cells are the major players of adaptive immunity. Since they are recruited 
into tumor microenvironment to eliminate tumor cells by inducing tumor cell apoptosis20, we analyzed the infil-
tration of these lymphocytes into B16 melanoma tumors. As shown in Fig. 4a, number of CD8+ T cells, but not 
that of CD4+ T cells, in the tumor formed in Pld2−/− mice was lower than that in the tumor in WT mice, which 
was confirmed with Pld2−/−/Cas9 mice (Supplementary Fig. S4). Similarly, number of CD8+ T cells but not CD4+ 
T cells in the LLC tumor formed in Pld2−/− mice was decreased (Supplementary Fig. S5). These results suggest 
that Pld2−/− mice are defective for development and/or infiltration of CD8+ T cells. To confirm this idea, we 
examined whether ablation of Pld2 in CD8+ T cells is responsible for enhanced tumor growth. WT or Pld2−/− 
CD8+ T cells were transferred with WT CD4+ cells into Rag1−/− mice, which lack all mature lymphocytes21, then 
B16 melanoma cells were implanted into those mice. Tumor growth was significantly greater in the mice received 
Pld2−/− CD8+ T cells than in the mice received WT CD8+ T cells (Fig. 4b). Taken together, these results suggest 
that PLD2 in CD8+ T cells plays a pivotal role in tumor growth suppression.
Ablation of Pld2 reduces the number of CD8+ T cells in the spleen. The developmental process of T 
lymphocytes includes several steps. Bone marrow-derived T lymphocytes first differentiate in the thymus: imma-
ture thymocytes, so called double negative CD4−/CD8− cells, differentiate into single-positive CD8+ or CD4+ 
naïve T cells through the positive and negative selection22. Naïve T cells then migrate to the secondary lymphoid 
organs such as the lymph node and spleen, where they are activated by antigen presenting cells, followed by clonal 
expansion and differentiation into effector/memory cells. These activated T lymphocytes migrate throughout 
the body to eventually reach to and attack infected or damaged tissues. When these T cells in the thymus and 
spleen were analyzed by flow cytometry, there was no obvious difference in the population of CD4+ and CD8+ 
thymocytes between WT and Pld2−/− tumor-bearing mice (Fig. 5a). On the other hand, a significant reduction 
in the population of CD8+ T cells was observed in Pld2−/− splenocytes (11.46 ± 2.07% versus 7.83 ± 3.44%), 
while CD4+ T cell population unchanged (Fig. 5b). Rag1−/− mice transferred with Pld2−/− CD8+ and WT CD4+ 
T cells also exhibited decreased population of CD8+ T cells in the spleen compared to Rag1−/− mice transferred 
with WT CD8+ and WT CD4+ T cells (Fig. 5c), confirming that ablation of Pld2 in CD8+ T cells is responsible 
for their reduced population in the spleen. These results raise a possibility that migration of naïve CD8+ T cells 
from the thymus to the spleen or their proliferation/expansion in the spleen is disrupted by the deletion of Pld2 
in CD8+ T cells.
TCR-stimulated proliferation of CD8+ T cells is impaired by deletion of Pld2. To clarify the pos-
sibility described above, we analyzed the in vitro chemotaxis ability of naïve CD8+ T cells isolated from the thy-
mus of WT and Pld2−/− mice. Chemotaxis of naïve CD8+ T cells purified from the Pld2−/− thymus towards the 
chemokines CCL21 and CXCL12, which have been implicated in naïve T lymphocyte trafficking to secondary 
lymphoid organs23,24, was comparable to that of WT CD8+ T cells (Supplementary Fig. S6). Thus, PLD2 is dispen-
sable for naïve CD8+ T cell migration.
Next, we analyzed the effects of Pld2 ablation on proliferation of splenic CD8+ T cells stimulated with 
anti-CD3 and -CD28 antibodies, which mimic stimulation by antigen-presenting cells, by the Carboxyfluorescein 
www.nature.com/scientificreports/
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Figure 2. Pld2 deletion suppresses apoptosis of tumor cells without effect on tumor angiogenesis. (a) Tumors 
produced by B16 melanoma cells were dissected at 16 days after implantation of the cell, and tumor sections 
were immunostained for CD31 (red) and alpha smooth muscle actin (α-SMA) (green) (left images). Nuclei 
were also stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). Blood vessel area (left graph) and number 
(middle graph), and number of mature vessels covered by α-SMA+ mural cells (right graph) were quantified 
(n = 6 for each genotype, at least 3 fields/section were captured). (b) Tumor sections were stained by the TUNEL 
method (green) and with DAPI (blue) (left images). Apoptotic cells in tumors were quantified (n ≥ 5 for each 
genotype). (c) B16 melanoma cells stably expressing mCherry (red) were implanted into WT and Pld2−/− mice, 
and apoptotic cells in tumors were detected by TUNEL assay (left images, green) (n ≥ 5 for each genotype). 
Arrows represent apoptotic B16 melanoma cells and arrowheads apoptosis of mCherry-negative cells. Right 
panel shows the quantification of apoptotic B16 melanoma cells in the field. (d) Sections of tumors produced 
as in (c) were immunostained for cleaved caspase-3 (green), and nuclei were stained with DAPI (blue) (left 
images). Apoptotic B16 melanoma cells were quantified as in (c) (right panel). All quantification data represent 
means ± SEM. *p < 0.05; ***p < 0.0005; n.s., not significant. Scale bars, 50 μm.
www.nature.com/scientificreports/
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diacetate succinimidyl ester (CFSE) fluorescence intensity method25. Purification of CD8+ T cells was more than 
95% (Supplementary Fig. S7). CD3/CD28 stimulation by antibodies increased the PLD enzymatic activity in 
CD8+ T cells, which was almost completely suppressed by the deletion of Pld2 (Supplementary Fig. S8), indi-
cating that PLD2 but not PLD1 is activated by CD3/CD28 stimulation to play a role in TCR-mediated cellular 
functions. CD3/CD28-stimulated decrease in CFSE intensities of CD8+ T cells with prolonged period of culture 
was slower in Pld2−/− CD8+ T cells (Fig. 6a), demonstrating that their proliferation is impaired by the Pld2 abla-
tion. Treatment of WT CD8+ T cells with the PLD2-specific inhibitor VU036473926 also suppressed their pro-
liferation (Fig. 6b), confirming that PLD2 is required for CD3/CD28-stimulated CD8+ T cell proliferation. On 
the other hand, any significant difference in the proliferation of WT and Pld2−/− CD4+ T cells was not observed 
(Supplementary Fig. S9). It was also found that apoptosis was promoted in Pld2−/− CD8+ T cells stimulated with 
anti-CD3 and -CD28 antibodies (Fig. 6c). Thus, PLD2 might be required for proliferation and survival of CD8+ T 
cells, which was supported by the result showing that expression levels of the PLD2 protein and mRNA in CD8+ 
T cells are higher than those in CD4+ T cells (Supplementary Fig. S10).
The inhibition of CD8+ T cell proliferation by Pld2 ablation may be resulting from the impaired CD8+ T cell 
activation. This possibility is unlikely because the ratio of the early activation markers CD25- and CD69-positive 
cells after stimulation of CD3/CD28 were both increased to the comparable levels in WT and Pld2−/− CD8+ T 
cells (Supplementary Fig. S11).
PLD2 is involved in Ras/Erk signaling pathway in CD8+ T cells. It is well known that engagement 
of the TCR activates the PI3K-Akt and Ras-Erk pathways which are critical for the T cell proliferation27,28. To 
elucidate the molecular mechanism how PLD2 regulates CD8+ T cell proliferation, we examined the involve-
ment of PLD2 in these pathways. In CD8+ T cells isolated from spleens of Pld2−/− mice, CD3/CD28-stimulated 
Erk phosphorylation was significantly suppressed, whereas Akt phosphorylation was unaffected by Pld2 abla-
tion (Fig. 7a,b). Furthermore, activation of Ras, the upstream activator of the Erk pathway, was inhibited in 
Pld2−/− CD8+ T cells (Fig. 7c). Production of interleukin-2 (IL-2), which is the downstream target gene prod-
uct of Erk and the extracellular signaling molecule for CD8+ T cell proliferation, decreased in Pld2−/− CD8+ 
T cells (Supplementary Fig. S12). In contrast, production of Interferon-γ (IFN-γ) and tumor necrosis factor-α 
(TNF-α), both of which are secreted from effector CD8+ T cells to resist against pathogens, was not affected by 
Pld2 ablation (Supplementary Fig. S12). The inhibition of Ras/Erk activation and IL-2 production is unlikely to 
be attributable to the downregulation of TCR or CD28: the cell surface levels of TCR and CD28 during the CD3/
CD28 stimulation were comparable between WT and Pld2−/− CD8+ T cells (Supplementary Fig. S13). Finally, 
Figure 3. Deletion of Pld2 from bone marrow cells promotes tumor growth. (a) Efficiency of bone marrow 
transplantation. Irradiated C57BL/6 mice with CD45.2-positive bone marrow cells were transplanted with 
CD45.2- (left) or CD45.1-positive bone marrow cells (right). Total bone marrow cells were isolated, and chimerism 
was analyzed by FACS using anti-CD45.1 and anti-CD45.2 antibodies. r, recipient; d, donor. (b) Tumor growth 
of B16 melanoma in WT and Pld2−/− mice transplanted with WT and Pld2−/− bone marrow cells. The pictures 
shown in the right are primary tumors dissected after 18 days of implantation. Data shown are means ± SEM 
(n = 6 for rWTdWT and rWTdKO; n = 5 for rKOdWT and rKOdKO). *p < 0.05.
www.nature.com/scientificreports/
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pharmacological inhibition of MEK, the upstream kinase of Erk, by the inhibitor U0126 demonstrated that sup-
pression of Erk phosphorylation is sufficient to inhibit CD3/CD28-stimulated proliferation of splenic CD8+ T 
cells (Supplementary Fig. S14). Taken together, PLD2 appears to be required for TCR-mediated activation of the 
Ras-Erk pathway and IL-2 production, which are essential cell events for TCR-stimulated proliferation of splenic 
CD8+ T cells.
Discussion
The results obtained in this study provide evidence that PLD2 in CD8+ T lymphocytes plays an important role 
in the TCR-mediated proliferation of these cells in the spleen by regulating the Ras-Erk signaling pathway and 
IL-2 production, thereby at least in part contributing to the anti-tumor immunity. We began this study with 
Pld2−/− mice, which have previously been generated17, and found that Pld2 deletion promoted tumor growth. In 
this result, it was our concern that a partial peptide is produced in the Pld2−/− mice, which have been generated 
by replacing exons 14 and 15 of the Pld2 gene, and exerts an off-target effect(s). However, this is not likely because 
the new Pld2-null mice, Pld2−/−/Cas9, which were generated by deleting most of coding regions of the Pld2 gene, 
showed the same phenotype. Thus, it can be concluded that PLD2 in CD8+ T cells plays an important role in the 
anti-tumor immunity.
Infiltration of leukocytes into tumor environment is a hallmark of anti-cancer immunity: tumor-associated 
macrophages and T cells are frequently found5,29. It has been shown that the mice transplanted with CD8+ T cells 
acquire both immediate and long-term protection from tumors: 93% and 30–60% of mice transplanted with 
Figure 4. Ablation of Pld2 in CD8+ T cells suppresses their infiltration into tumors and promotes tumor 
growth. (a) Infiltration of T cells into tumors formed in WT and Pld2−/− mice was analyzed by immunostaining 
for CD8 (upper images) and CD4 (lower images). The number of T cells was counted (right panels) (n = 6 
for each phenotype, at least 4 fields/section were captured). ***p < 0.0005; n.s., not significant. (b) Growth 
of B16 melanoma tumor produced in Rag1−/− mice transplanted with WT or Pld2−/− CD8+ T cells together 
with WT CD4+ T cells was analyzed. Weight of the tumors dissected at day 16 were measured and shown as 
means ± SEM in the left graph (n = 6). *p < 0.05. Shown in the right images are tumors dissected at day 16.
www.nature.com/scientificreports/
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CD8+ T cells were tumor-free when they were challenged with tumors after 1 day and 90 days after transplanta-
tion, respectively30. In addition, Sato et al. have reported that among tumor-infiltrating lymphocytes (TILs), only 
intraepithelial CD8+ TILs were associated with improved survival of epithelial ovarian cancer patients31. These 
reports provide evidence for the central role of CD8+ T cells in anti-tumor immunity. Furthermore, CD8+ T 
cells eliminate target cells including tumor cells by inducing apoptosis32, and in this study we observed decreased 
CD8+ T cell infiltration in tumors formed in Pld2−/− mice concomitantly with the reduced number of apoptotic 
tumor cells. These lines of evidence are consistent with the notion that impaired CD8+ T cell infiltration into 
tumor microenvironment in Pld2−/− mice promotes tumor growth.
In the present study, we focused on the function of PLD2 in CD4+ and CD8+ T cells to elucidate the patho-
logical function of PLD2 in tumor growth. However, we cannot still rule out the possibility that PLD2 in other 
immune cells is also involved in suppression of tumor growth. Several lines of evidence demonstrate that PLD2 
regulates functions of some immune cells distinct from T lymphocytes. In a macrophage cell line RAW/LR5, 
PLD2 participates in cell chemotaxis33, and is required for phagocytosis of both macrophages and neutrophils12,34. 
Furthermore, deficiency of Pld2 impairs the migration and extravasation of primary neutrophils12. These reports 
indicate the possibility that PLD2 contributes to anti-tumor immunity through these immune cell functions. It is 
Figure 5. Number of CD8+ T cells decreases in the spleen of Pld2−/− mice. (a,b) Thymocytes (a) and 
splenocytes (b) isolated from tumor-bearing mice were stained with anti-CD4 and anti-CD8 antibodies, and 
subjected to FACS analysis. Alive lymphocytes were gated and total of 5 × 104 cells were analyzed (left panels). 
Data shown are representative of two independent experiments (n ≥ 5 for each experiment). Populations 
of CD4+ and CD8+ cells were calculated and shown as means ± SEM in the right graphs. *p < 0.05; n.s., 
not significant. (c) Populations of CD4+ and CD8+ T cells in the spleens of tumor-bearing Rag1−/− mice, in 
which T cells were transplanted as in Fig. 4b, were analyzed with the FACS system (left panels), and shown as 
means ± SEM in the right graph (n = 6). **p < 0.01; n.s., not significant.
www.nature.com/scientificreports/
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also of great interest to elucidate whether PLD2 regulates functions of regulatory T (Treg) cells, which suppress T 
cell-mediated immune responses35. If PLD2 negatively regulates the effector T cell-suppressive function of Treg 
cells, ablation of Pld2 from Treg cells would interfere with the anti-tumor immune response of CD8+ T cells. Since 
inhibition of Treg cell function strongly suppresses tumor progression36,37, clarification of the PLD2 involvement 
in the function of Treg cells might provide insight into anti-cancer immunotherapies.
Although we showed that PLD2 is critical for proliferation and survival of activated CD8+ T cells, thereby 
contributing to suppression of tumor growth, PLD2 in other types of cells distinct from immune cells might be 
also involved in the suppression of tumor growth. This notion is derived from the observations that tumor growth 
in WT mice transplanted with Pld2−/− bone marrow cells was slower than that in Pld2−/− mice transplanted with 
Figure 6. PLD2 is required for proliferation and survival of splenic CD8+ T cells. (a) Splenic CD8+ T cells 
isolated from WT and Pld2−/− mice were labeled with CFSE, and stimulated with immobilized anti-CD3 and 
soluble anti-CD28 antibody for the indicated days. Proliferation of alive WT (upper panels) and Pld2−/− CD8+ 
T cells (lower panels) was analyzed by measuring CFSE fluorescence with the FACS system (left panels). 
Percentage of CFSE-positive CD8+ T cells is shown in the right graph as means ± SEM from at least three 
independent experiments (n = 6 for each group). *p < 0.05. (b) Splenic CD8+ T cells isolated from WT mice 
were treated with or without the PLD2 inhibitor VU0364739, and their proliferation was analyzed as in (a). 
DMSO was used as a control. The number in each panel represents the percentage of CFSE-positive cells. (c) 
Splenic CD8+ T cells were isolated and stimulated as in (a). The proportion of apoptotic CD8+ T cells was 
evaluated by Annexin V staining and FACS analysis (left panels). Shown in FACS graphs are the representatives 
of three independent experiments (n = 9 for each group). Quantified data are expressed as means ± SEM. 
*p < 0.05.
www.nature.com/scientificreports/
9SCientiFiC REPORTS |  (2018) 8:6283  | DOI:10.1038/s41598-018-24512-x
Pld2−/− bone marrow cells, and that tumor growth in Pld2−/− mice transplanted with WT bone marrow cells 
tended to be stimulated compared with that in WT mice transplanted with WT bone marrow cells (Fig. 3b). It is 
known that the interaction between tumor cells and stromal cells is critical in tumor progression: both types of 
cells mutually support their proliferation by secreting and recognizing growth factors, such as epidermal growth 
factor (EGF), in an autocrine/paracrine manner, thereby promoting tumor growth38. Since PLD2 has been 
reported to promote the EGF receptor (EGFR) endocytosis through the activation of the Dynamin GTPase39, 
PLD2 might inhibit the EGF/EGFR circuit among tumor cells and stromal cells by limiting cell surface EGFR of 
stromal cells.
Recently, Ghim et al. have reported that tumor angiogenesis is inhibited in endothelial cell-specific Pld2 con-
ditional knockout mice40, demonstrating that PLD2 in vascular endothelial cells is essential for tumor angio-
genesis. On the other hand, we did not observe any changes in tumor angiogenesis in Pld2−/− mice (Fig. 2a), 
even though PLD2 could be deleted from vascular endothelial cells in these mice. Although we cannot clearly 
explain why these two studies showed different phenotypes, it is possible that pro-angiogenic and anti-angiogenic 
functions of vascular endothelial cells and other cell types, respectively, are balanced in Pld2−/− mice; therefore, 
Pld2−/− mice did not exhibit apparent changes in tumor angiogenesis. It is also plausible that PLD2 in some 
types of cells in tumor microenvironment is involved in inhibition of pro-angiogenic factor production/secretion. 
Further studies are required to clarify these issues.
In the dissection of the signaling pathways for the PLD2-mediated T cell proliferation, we found that PLD2 
activates Ras and subsequently promotes phosphorylation of Erk1/2 in the CD3/CD28-stimulated primary cul-
tured CD8+ T cells. However, it still remains to clarify the activation mechanism of Ras by PLD2. Mor et al. have 
suggested that PLD2 activates Ras through the action of RasGRP1, the guanine nucleotide-exchange factor (GEF) 
Figure 7. PLD2 is involved in activation of Ras and Erk in CD3-/CD28-costimulated CD8+ T cells. (a) Primary 
splenic CD8+ T cells were stimulated as in Fig. 6a for indicated time, and phosphorylation of Erk and Akt was 
analyzed by Western blotting. (b) Phosphorylation levels of Erk (left) and Akt (right) in (a) were quantitated. 
Shown are means ± SEM from three independent experiments (n = 6 for each genotype). *p < 0.05. (c) Splenic 
CD8+ T cells were stimulated as in (a) and activation of Ras was assessed by the pull-down assay using the Ras 
activation assay kit (Millipore). Shown are representative of two independent experiments.
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of Ras, at the plasma membrane in Jurkat cells co-stimulated with TCR and lymphocyte function-associated 
antigen-1 (LFA-1)41. Furthermore, Salzer et al. have recently indicated that RasGRP1-deficient CD8+ T cells pre-
pared from immunodeficient patients show reduced Erk1/2 phosphorylation42. From these reports, it is reasona-
ble to speculate that upon TCR engagement of CD8+ T cells, PLD2 recruits the Ras GEF RasGRP1 to the plasma 
membrane to activate Ras, which in turn activates Erk1/2 to promote cell proliferation and survival. A distinct 
Ras GEF might also be involved in Ras activation, because Son of sevenless 1 (Sos1), another Ras GEF, has been 
reported to be involved in T cell proliferation by persistently activating Erk downstream of TCR43. Interestingly, 
PA directly binds to the PH domain of Sos1 and recruits it to the plasma membrane to activate Ras44. Since 
TCR-stimulated PLD enzymatic activity in CD8+ T cells mostly depends on PLD2 (Supplementary Fig. S7), it 
is plausible that PLD2 activates Ras by recruiting Sos1 to the plasma membrane through its product PA. The 
detailed mechanism for the PLD2 activation of Ras remains to be elucidated by the future analysis.
Although we showed that PLD2 regulates CD8+ T cell proliferation through the Ras-Erk pathway, involve-
ment of an additional pathway(s) cannot be excluded. Several lines of evidence demonstrate that c-Jun amino 
terminal kinase (JNK), another member of the MAP kinase family, is involved in the regulation of CD8+ T cell 
functions. Conze et al. (2002) reported that the absence of JNK2 increases IL-2 production and proliferation of 
CD8+ T cells. On the other hand, CD8+ T cells lacking JNK1 are unable to undergo antigen-stimulated expansion 
in vitro45. In addition, Gao et al. (2005) indicated that deletion of Jnk1 from CD8+ T lymphocytes reduces per-
forin expression and impaired CTL functions, which are responsible for tumor susceptibility46. It is of interest to 
examine whether JNK is regulated by PLD2 in TCR-stimulated CD8+ T cells.
Interestingly, we found that PLD2 in CD8+ T cells is involved in production of IL-2, which regulates multi-
ple immune response-related functions of CD8+ T cells, including clonal expansion/proliferation, memory gen-
eration, cytotoxicity, and IFN-γ production47,48. The study on Il-2-deficient mice showed that although CD8+ 
T cells can be weakly activated and elicit cytotoxicity during infection in an IL-2-independent mechanism, 
infection-dependent cell expansion exclusively requires IL-2, suggesting that IL-2 plays a unique role in prolifer-
ative responses of CD8+ T cell48. Since IL-2 produced in and secreted from CD8+ T cells contributes to prolifer-
ation of CD8+ T cells in an autocrine/paracrine way, our findings indicate that IL-2 is the one of the major target 
genes for the PLD2-Ras-Erk axis to promote CD8+ T cell proliferation.
In this study, we used two different cancer cell lines, B16 melanoma and Lewis lung carcinoma, to induce 
tumor formation in mice. From the unexpected observation of tumor growth in two independent knockout mice 
models, we uncovered the novel function of PLD2 in CD8+ T cell proliferation. Since CD8+ T cells eliminate var-
ious types of cancer, it is of interest to examine progression of other types of cancer in Pld2-deleted mice.
Recent advances in understanding anti-tumor immunity have provided insight into new approaches for can-
cer treatment. The results in this study provide insight into the mechanism governing anti-tumor immunity 
and could contribute to improve cancer immunotherapy. Screening of chemical libraries to activate PLD2 or 
creation of membrane permeable PA could be a new strategy for the treatment of cancers and immunodeficiency 
disorders.
Materials and Methods
Mice. Pld2−/− mice with C57BL/6 background were described previously17. Pld2−/−/Cas9 mice were gener-
ated as described in the report by Mizuno et al.49, and a schematic representation of Pld2 targeting is shown in 
Supplementary Fig. S1. Briefly, we determined the candidate CRISPR target sequences of the Pld2 gene using the 
website CRIPR direct (https://crispr.dbcls.jp/). Oligo DNAs for the respective target sequences were designed 
and inserted into the px300 vector (Addgene plasmid 42230) to generate px300-Pld2, which expresses gRNA 
for the Pld2 gene and the Cas9 protein. The cleavage efficiencies of the target sequences by these vectors were 
evaluated by the pCAG-EGxxFP (Addgene plasmid 50716) system49. The gRNA for position 163–185 of the Pld2 
gene was selected according to its highest efficiency. The donor oligo DNA containing stop codons in three dif-
ferent frames was designed for homology-directed repair (HDR)-mediated gene modification (Supplementary 
Fig. S1). The px300-Pld2 and the oligo donor were injected into pronuclei of one-cell-stage embryos collected 
from C57BL/6 mice. The injected embryos were then transferred into pseudopregnant ICR mice. Targeted 
mice were screened by PCR genotyping and direct sequencing of the tail DNA genome using the primers of 
5′-GCCATCTATGACCTTCAGCCTCTGAAAGC-3′ and 5′-GTCTTCTGGCCCAACCCAGGCCTCCACTT-3′. 
Age- and sex-matched 8 to 12 weeks-old mice were used in the experiments. All experiments with mice were con-
ducted according to the Guidelines for Proper Conduct of Animal Experiments, Science Council of Japan, and 
protocols were approved by the Animal Care and Use Committee, University of Tsukuba.
Cell culture. B16 melanoma cells with or without stable expression of mCherry and Lewis lung carcinoma 
(LLC) cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Nacalai Tesque) containing 
10% fetal bovine serum (FBS; Gibco) and 1% penicillin-streptomycine (P/S) (Nacalai Tesque). Primary CD4+ 
T cells and CD8+ T cells were cultured in RPMI1640 (Nacalai Tesque) supplemented with 10% FBS, 50 μM 
2-mercaptoetanol and 2% P/S at 37 °C under 5% CO2.
Assay for tumor growth. B16 melanoma (106 cells) or LLC cells (2.5 × 105 cells) suspended in 100 μl of 
serum-free DMEM were subcutaneously transplanted into the dorsal flank of 8 weeks-old mice. Tumor volume 
was measured by digital caliper every other day after sixth day of implantation, and calculated according to the 
following formula: tumor volume = length × (width)2 × 0.52. After 16 or 18 days of implantation, tumors were 
dissected, fixed in 4% FPA/PBS at 4 °C for 4 hr, followed by incubation in 30% sucrose at 4 °C overnight, and sub-
jected to immunohistochemistry analyses.
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Immunohistochemistry. Tumors were sliced into 7 μm-thick sections, fixed with 4% paraformaldehyde/
PBS for 10 min at room temperature (RT), and blocked with TNB buffer [0.1 M Tris-HCl, pH 7.5, 0.15 M NaCl, 
0.5% TSA blocking reagent (PerkinElmer)] for 1 hr at RT. To analyze tumor angiogenesis, sections were incubated 
with anti-PECAM1 (1:200 dilution; Biolegend) and -α-SMA (1:200 dilution; Abcam ab5649) antibodies at 4 °C 
overnight. To examine tumor-infiltrated T cells, sections were incubated with primary antibodies against CD4 
(clone GK1.5) and CD8 (clone 53–6.7) (1:200 dilution; Biolegend) at 4 °C overnight, and subsequently with Alexa 
488-conjugated secondary antibodies (1:1000 dilution; Invitrogen). Fluorescence signals were observed using the 
fluorescence microscope Biozero (KEYENCE).
Assay for apoptosis. Cell apoptosis was analyzed by the TUNEL assay and immunostaining of cleaved 
caspase-3. TUNEL assay was performed using the In Situ Cell Death Detection Kit Fuorescein (Roche) according 
to the manufacturer’s instruction. In brief, tumor sections were fixed with 4% FPA/PBS for 15 min at RT and 
permeabilized with 0.1% Triton X/0.1% sodium citrate for 5 min on ice. After washing with PBS/0.1% BSA, sec-
tions were labeled with the TUNEL reaction mixture at 37 °C in the dark for 60 min. For the detection of cleaved 
caspase-3, tumor sections were immunostained with the anti-cleaved caspase-3 antibody (Cell Signaling, #9661) 
as described above. The number of apoptotic cells and B16 melanoma-apoptotic cells were evaluated by capturing 
both the peripheral and central fields of each section (at least 4 fields/section).
Flow cytometry. Splenocytes and thymocytes were isolated from the spleen and thymus, respectively. Red 
blood cells were lysed with Tris-buffered ammonium chloride (ACTB) and remaining cells were sequentially 
filtered through 70 μm and 45 μm membranes to remove cell aggregates. Cells were blocked with anti-mouse 
CD16/32 antibodies (Biolegend), and stained with FITC-conjugated anti-CD8, APC-conjugated anti-CD4 anti-
bodies (Biolegend), and propidium iodide (PI), which stains dead cells. Flow cytometry was performed with the 
BD FACSCalibur cytometer (BD Bioscience) and data were analyzed using the BioCell Quest software.
Isolation of primary T cells. Primary CD4+ and CD8+ T cells were purified from splenocytes and thymocytes 
by negative selection. In brief, splenocytes and thymocytes were incubated with the biotinylated antibody cocktail 
including 0.5 µg/106 cells of anti-B220, -CD19, -IgM, -MHCII, -CD49b, -CD16/32, -Cd11c, -CD11b, -Ly-6G/6 C, 
-CD24, and -CD4 or -CD8 antibodies (Biolegend) at 4 °C for 30 min: the cocktail contained anti-CD4 or -CD8 
antibody for CD8+ or CD4+ T cell purification. Dynabeads MyOne Streptavidin C1 (Invitrogen) was added to the 
cell suspension and incubated with rotation for 30 min at 4 °C. Cell suspension was placed in a magnet for 2 min to 
remove bead-bound cells and the supernatant which contains target cells was collected. Isolated T cells were incu-
bated for 3–4 hr in RPMI 1640 containing 10% FBS and 2% P/S at 37 °C, 5% CO2, then subjected to assays for cell 
migration and in vitro proliferation.
Cell migration assay. Primary CD8+ T cells suspended in RPMI1640 were placed in the upper chamber of 
trans-well migration chambers (5 μm pore size; Corning). The lower chamber was filled with RPMI1640/0.1% 
BSA supplemented with or without 50 ng/ml of the chemokine, recombinant murine SDF-1α (CXCL12) 
(Peprotech) or recombinant murine Exodus-2 (CCL21) (Peprotech). After 3 hr of incubation, migrated cells 
in the lower chamber were collected by centrifuge at 2,000 × g for 10 min, and counted with haemocytometer. 
Migrated cells were expressed as % of total initial cells in the upper chamber.
Bone marrow transplantation. Recipient WT or Pld2−/− mice were irradiated with X-ray (Hitachi MBR-
1520R-3) at 4.5 Gγ twice at an interval of 4 hr. Bone marrow cells were isolated from donor WT or Pld2−/− mice, 
and 5 × 106 cells suspended in PBS were intravenously injected into irradiated recipient mice after 24 hr of irradi-
ation. At 12 weeks after irradiation, tumor cells were implanted.
T cell transplantation. Either WT or Pld2−/− CD8+ T cells (5 × 106 cells) and WT CD4+ T cells (7 × 106 
cells) suspended in PBS were injected i.v. into Rag1−/− recipient mice. One week after transplantation, B16 mela-
noma cells were implanted as described above.
In vitro cell proliferation assay. CD8+ T cells (3 × 107 cells) isolated from the spleen of WT or Pld2−/− 
mice were labeled with the fluorescent dye CFSE (3 μM). In the experiments with the PLD2 inhibitor VU0364739 
(1 μM or 2 μM; Tocris Bioscience #4171) or the MEK inhibitor U0126 (5 μM; Cell Signaling #9903), cells were 
treated with inhibitors for 2 hr before labeling with CFSE. Cells were then seeded on the 6-well plate at 3 × 106 
cells/well and stimulated with 5 μg/ml of anti-CD3 antibody (clone 17A2; Biolegend) pre-bound to the cul-
ture plate and 2 μg/ml of soluble anti-CD28 antibody (clone 37.51; Biolegend) at 37 °C for the indicated days. 
Proliferation capacity of the cell was analyzed by tracing dilution of CFSE fluorescent intensity by flow cytometry.
Measurement of PLD activity. CD8+ T cells (2 × 107 cells/ml) isolated from the spleen of WT or Pld2−/− 
mice were suspended in RPMI 1640/1% FBS and incubated with [3H]lyso-PAF (5 µCi/ ml) at 37 °C for 1 hr to 
label PC in lymphocytes. Cells were washed with PBS/1% FBS for 3 times, suspended in HBSS/1% FBS plus 1% 
ethanol at 5 × 106 cells/ml, and co-stimulated with antibodies against CD3 and CD28 as described above for 
the indicated time. Cell lipids were extracted and separated by thin-layer chromatography on a silica gel plate. 
Phosphatidylethanol (PEt), the PLD-specific product in the presence of ethanol, was visualized by iodine staining, 
and the radioactivity of PEt was measured as described previously17. PEt production was calculated by dividing 
the radioactivity of PEt by that of the total phospholipids.
Assay for cytokine production in CD8+ cells. CD8+ T cells isolated from the spleen of WT and Pld2−/− 
mice were seeded on 12-well plates at 2 × 105 cells/well and stimulated with anti-CD3/CD28 antibodies for 24 hr 
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as described above. Brefeldin A (eBioscience) was added to the culture for the final 6 hr incubation to block 
cytokine secretion. Cells were collected and stained for CD8 with anti-CD8 antibody for 30 min at 4 °C, fol-
lowed by fixation and permeabilization with the Intracellular Fixation and Permeabilization buffer set (eBio-
science). After washing, antibodies against IL-2 (clone JES6–5H4; BD Biosciences), IFN-γ (clone XMG1.2; BD 
Biosciences) and TNF-α (clone MP6-XT22; BD Biosciences) were added to the cells and subjected to flow cytom-
etry analysis, and cell number producing these cytokines was counted.
Western blotting. To analyze the expression levels of PLD2, mouse brain and isolated primary T lympho-
cytes were lysed in urea buffer (8 M urea, 50 mM Tris-HCl, pH 6.8, 0.01% SDS, 0.01% β-mercaptoethanol, and 
0.001% bromophenol blue) and in lysis buffer (1% Nonidet P-40; 150 mM NaCl; 50 mM Tris with protease inhib-
itor), respectively. After lysates were sonicated, proteins in the lysate were separated by 10% SDS-polyacrylamide 
gel electrophoresis, and transferred onto the PDVF membrane. The membrane was blocked with Blocking Buffer 
(TOYOBO) for 1 hr at RT and incubated with the anti-PLD2 antibody17 diluted (1:1000) in the Can get signal kit 
(TOYOBO) at 4 °C overnight.
For detection of phosphorylated Erk and Akt, CD8+ T cells were activated with anti-CD3 and -CD28 anti-
bodies and lysed in the lysis buffer supplemented with phosphatase inhibitors as described above. After separa-
tion of proteins of lysates and transfer to PDVF membranes, membranes were incubated at 4 °C overnight with 
primary antibodies for phospho-p44/42 MAPK (Thr202/Tyr204) (Cell signaling), p44/42 MAPK (Erk1/2) (Cell 
Signaling), phosho-Akt (T308) (Cell Signaling), and Akt (Cell Signaling) which were diluted in 1% BSA/0.05% 
Tween 20/PBS (1:1000). Membranes were subsequently incubated with HRP-conjugated secondary antibodies 
(Cell Signaling) at RT for 1 hr. The signals were detected by the luminescent image analyzer LAS-4000 mini 
(Fujifilm, Japan) and phosphorylation levels of p-Erk and p-Akt were analyzed by the Multi Gauge software 
(Fujifilim, Japan).
Statistical analyses. All experiments were presented as the mean ± SEM. The statistical analysis was per-
formed using an unpaired two tail - Student’s t-test. P-values < 0.05 were considered to be statistically significant.
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